Guanjing Chen - Concepedia

Author

Guanjing Chen

Vertex Pharmaceuticals (United States)

Also Known As

Guanjing Chen

Publications

578

Citations

H-Index

Concepts

All Affiliations

Vertex Pharmaceuticals (United States)Novartis (United States)AstraZeneca (United States)Arisan Therapeutics (United States)Amgen (United States)

About

Guanjing Chen is an author at Vertex Pharmaceuticals (United States) specializing in medicine, cell biology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	578
2	Health Sciences	2	2	41
3	Natural Sciences	2	2	198
4	Biochemistry	2	2	198
5	Biomolecular Engineering	2	2	262

Guanjing Chen

Publications

578

Citations

H-Index

Page 1

	Year	Citations
Small-molecule WNK inhibition regulates cardiovascular and renal function Ken Yamada, Hyi-Man Park, Dean F. Rigel, Nature Chemical Biology Molecular PhysiologyKidney ResearchMedicinePhysiologyPharmacology	2016	162
Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control Alex M. Aronov, Qing Tang, Gabriel Martínez-Botella, Journal of Medicinal Chemistry Drug TargetChemical BiologyTumor BiologyMedicinal ChemistrySelective Pyrimidylpyrrole Inhibitors	2009	144
Flipped Out: Structure-Guided Design of Selective Pyrazolylpyrrole ERK Inhibitors Alex M. Aronov, Christopher Baker, Guy W. Bemis, Journal of Medicinal Chemistry Medicinal ChemistryDrug TargetMedicineReceptor Tyrosine KinaseRational Drug Design	2007	118
Kinetic Mechanism of the p38-α MAP Kinase: Phosphoryl Transfer to Synthetic Peptides Guanjing Chen, Margaret Porter, John R. Bristol, Biochemistry Molecular BiologySynthetic PeptidesPeptide ScienceKinetic MechanismMolecular Pharmacology	2000	54
Identification of a PCSK9-LDLR disruptor peptide with in vivo function Margaret E. Brousseau, Kevin B. Clairmont, Glen Spraggon, Cell chemical biology InflammationSignal TransductionPeptide LibraryImmunologyPcsk9-ldlr Disruptor Peptide	2021	42
Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance Ursula A. Germann, Brinley F. Furey, Jeff Roix, Cancer Research Chemoprevention StrategyCancer BiologyTumor BiologyDrug ResistanceOncology	2015	21
Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/Stem Cell Factor Receptor (FLT3/c-KIT) Inhibitor for the Treatment of Acute Myelogenous Leukemia Robert J.O. Davies, Albert C. Pierce, Cornelia J. Forster, Journal of Medicinal Chemistry Excellent PotencyMixed-phenotype Acute LeukemiaAcute Myelogenous LeukemiaMyeloid NeoplasiaHematological Malignancy	2011	20
VX-322: A Novel Dual Receptor Tyrosine Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia David K. Heidary, George Q. Huang, Diane M. Boucher, Journal of Medicinal Chemistry Hematological MalignancyNovel TherapyMedicineMixed-phenotype Acute LeukemiaMalignant Blood Disorder	2012	17

Page 1